Adallen Pharma Limited, headquartered in Great Britain, is a prominent player in the pharmaceutical industry, specialising in the development and distribution of innovative healthcare solutions. Founded in 2015, the company has rapidly established itself in key operational regions across Europe and beyond, focusing on advanced drug formulations and delivery systems. With a commitment to quality and efficacy, Adallen Pharma offers a range of core products, including prescription medications and over-the-counter solutions that address various health conditions. Their unique approach to research and development has led to several notable achievements, positioning them as a trusted name in the market. As they continue to expand their portfolio, Adallen Pharma remains dedicated to improving patient outcomes through cutting-edge pharmaceutical advancements.
How does Adallen Pharma Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Adallen Pharma Limited's score of 26 is lower than 52% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, Adallen Pharma Limited reported total carbon emissions of approximately 260,000 kg CO2e, with emissions distributed across various scopes. The breakdown includes 1,000 kg CO2e from Scope 1, primarily from mobile combustion (600 kg CO2e), and 2,690 kg CO2e from Scope 2, all attributed to purchased electricity. The majority of emissions stem from Scope 3, amounting to about 256,310 kg CO2e, which includes significant contributions from purchased goods and services (231,000 kg CO2e) and upstream transportation and distribution (20,800 kg CO2e). Despite the substantial emissions figures, Adallen Pharma Limited has not set specific reduction targets or climate pledges, indicating a potential area for improvement in their sustainability strategy. The company does not inherit emissions data from a parent organization, and all reported figures are derived directly from their own operations. As the pharmaceutical industry increasingly focuses on sustainability, Adallen Pharma Limited's commitment to addressing its carbon footprint will be crucial in aligning with global climate goals.
Access structured emissions data, company-specific emission factors, and source documents
2023 | |
---|---|
Scope 1 | - |
Scope 2 | 5,000 |
Scope 3 | 54,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Adallen Pharma Limited is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.